clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bacteriuria D001437 7 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bradycardia D001919 13 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Savarino V et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10886045
Saito K et al. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. 2000 Gastrointest. Endosc. pmid:10882958
Yanagihara K et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. 2000 J. Antimicrob. Chemother. pmid:10882691
Delchier JC [How to eradicate Helicobacter pylori?]. 1999 Gastroenterol. Clin. Biol. pmid:10880913
Erel F et al. Impact of Helicobacter pylori and Giardia lamblia infections on chronic urticaria. 2000 Mar-Apr J Investig Allergol Clin Immunol pmid:10879997
Suzuki K et al. [Fibrosing alveolitis following Legionella pneumonia]. 2000 Nihon Kokyuki Gakkai Zasshi pmid:10879037
Maggiolo F et al. In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus. 2000 J Chemother pmid:10877512
Amayasu H et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. 2000 Ann. Allergy Asthma Immunol. pmid:10875487
Fraser AG et al. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. 1999 Aust N Z J Med pmid:10868529
Mikasa K [Study of effects and mechanisms of macrolide as biological response modifier for lung cancer treatment]. 2000 Jpn J Antibiot pmid:10868303
Drago L et al. Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. 2000 Jul-Aug Chemotherapy pmid:10859433
Miltner EC and Bermudez LE Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10858369
Hirschl AM et al. In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. 2000 Antimicrob. Agents Chemother. pmid:10858365
Hammerschlag MR and Roblin PM Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. 2000 Int. J. Antimicrob. Agents pmid:10854812
Nagahara A et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. 2000 Helicobacter pmid:10849057
Bhasin DK et al. Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India. 2000 Helicobacter pmid:10849056
Leiper K et al. Open label trial of oral clarithromycin in active Crohn's disease. 2000 Aliment. Pharmacol. Ther. pmid:10848665
Ammon S et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:10848660
Katelaris PH et al. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. 2000 Aliment. Pharmacol. Ther. pmid:10848659
Moayyedi P et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. 2000 Aliment. Pharmacol. Ther. pmid:10848655
Zullo A et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:10848654
Baños F et al. [Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study]. 2000 Med Clin (Barc) pmid:10846695
Romero Gómez M et al. [Usefulness of Helicobacter pylori antigen detection in stools in the diagnosis of infection and confirming eradication after treatment]. 2000 Med Clin (Barc) pmid:10846675
Laine L et al. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. 2000 Gastrointest. Endosc. pmid:10840297
Kaushik SP and Vu C Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication. 2000 Aust N Z J Med pmid:10833116
Gisbert JP et al. One-week therapy with pantoprazole versus ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. 2000 Eur J Gastroenterol Hepatol pmid:10833090
Miyashita N et al. In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains. 2000 Microbiol. Immunol. pmid:10832970
Spiegel JR et al. Prolonged ulcerative laryngitis. 2000 Ear Nose Throat J pmid:10832196
Flockhart DA et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. 2000 J Clin Psychopharmacol pmid:10831018
Zuckerman JM The newer macrolides: azithromycin and clarithromycin. 2000 Infect. Dis. Clin. North Am. pmid:10829265
Rhee CS et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. 2000 Ann. Otol. Rhinol. Laryngol. pmid:10823478
Suzuki H et al. Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. 2000 May-Jun ORL J. Otorhinolaryngol. Relat. Spec. pmid:10810255
Azuma T et al. Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. 2000 Aliment. Pharmacol. Ther. pmid:10807427
Boruchoff SE et al. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. 2000 Clin. Pharmacol. Ther. pmid:10801243
Boyanova L et al. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. 2000 J. Med. Microbiol. pmid:10798553
Vernet Vernet M et al. [Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians]. 2000 Aten Primaria pmid:10795440
Shimizu T et al. Successful treatment using clarithromycin for a cutaneous lesion caused by Mycobacterium szulgai. 2000 Br. J. Dermatol. pmid:10792258
Calvet X et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10792124
Marini RP et al. Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. 1999 Am. J. Vet. Res. pmid:10791942
Waites K et al. Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. 2000 J. Clin. Microbiol. pmid:10790089
Shibl AM et al. Penicillin-resistant and -intermediate Streptococcus pneumoniae in Saudi Arabia. 2000 J Chemother pmid:10789552
Kane CL et al. Disseminated cutaneous Mycobacterium chelonae infection. 2000 Mar-Apr Cancer Control pmid:10783823
Abisheganaden JA et al. Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial. 2000 Am. J. Med. pmid:10781777
Fujimura S et al. Clarithromycin-susceptible Helicobacter pylori with mutation in 23S rRNA gene by PCR-RFLP method. 2000 J. Gastroenterol. pmid:10777165
Najib MM et al. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. 2000 Pharmacotherapy pmid:10772376
Singer J et al. Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group. 2000 Int J STD AIDS pmid:10772083
Adamsson I et al. Microbial ecology and treatment of Helicobacter pylori infections: review. 2000 J Chemother pmid:10768510
Bojarski C et al. Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. 2000 Z Gastroenterol pmid:10768243
Offman E et al. Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia. 2000 Chest pmid:10767245
Gasbarrini A et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. 2000 Scand. J. Gastroenterol. pmid:10766318